𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety of liver transplantation with chagas disease–seropositive donors for seronegative recipients

✍ Scribed by Fernando Salvador; Oscar Len; Israel Molina; Elena Sulleiro; Silvia Sauleda; Itxarone Bilbao; Lluis Castells; Teresa Pont; Joan Gavaldà; Albert Pahissa

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
91 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

The shortage of organs for transplantation has prompted the investigation of extended criteria donors, such as donors with transmissible infectious diseases. Here we report our recent experience with liver transplantation using organs from donors who were serologically positive for Chagas disease. We also provide a review of the literature and emphasize donor screening and preventive measures. Liver Transpl 17:1304-1308, 2011. V C 2011 AASLD.

📜 SIMILAR VOLUMES

Valganciclovir as preemptive therapy for
Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts
✍ Nina Singh; Cheryl Wannstedt; Lois Keyes; Debra Mayher; Lisa Tickerhoof; Mohamed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RϪ/Dϩ) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio

Transmission of T. cruzi infection via l
Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease
✍ Laura Barcán; Concepción Lunaó; Liliana Clara; Angel Sinagra; Alejandra Valledor 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Chagas' disease is an endemic zoonosis of South America caused by a protozoan parasite Trypanosoma cruzi. About 30% of infected people develop the disease. This disease is known to reactivate in immunocompromised hosts, such as patients with acquired immunodeficiency syndrome, leukemia, and transpla

Biliary complications following liver tr
Biliary complications following liver transplantation in the model for end-stage liver disease era: Effect of donor, recipient, and technical factors
✍ Theodore H. Welling; David G. Heidt; Michael J. Englesbe; John C. Magee; Randall 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

Biliary complications remain a significant problem following liver transplantation in the Model for End-Stage Liver Disease (MELD) era. We hypothesized that donor, recipient, and technical variables may differentially affect anastomotic biliary complications in MELD era liver transplants. We reviewe

Feasibility and safety of percutaneous c
Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation
✍ Babak Azarbal; Paul Poommipanit; Boris Arbit; Antoine Hage; Jignesh Patel; Miche 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

Percutaneous coronary intervention (PCI) has traditionally not been an option for patients with end-stage liver disease (ESLD) and coronary artery disease (CAD). This retrospective study was designed to demonstrate the feasibility and safety of PCI in liver transplant candidates. Patients with ESLD

MELD / PELD and the allocation of deceas
MELD / PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson's disease
✍ Russell H. Wiesner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

## Key Points 1. Historical perspective of donor allocation to patients with fulminant hepatic failure (FHF). 2. Predicting prognosis in patients with FHF using the London and Clichy criteria. 3. Model for end-stage liver disease (MELD) is a predictor of mortality in patients with FHF. 4. Outcomes